Bullish Case: Positive clinical trial results for AMT-130 are anticipated, potentially leading to late-stage trials. This could bolster investor confidence and inflate QURE's stock price significantly, outweighing current negative sentiment.

Bearish Case: Ongoing mixed results and negative market reactions to AMT-130 could catalyze further declines in stock price, compounded by the company’s shaky financial health and high operational costs.

Potential Outcomes:

• 60% chance: AMT-130 demonstrates critical benefits, raising QURE stock significantly.
• 30% chance: Data failures negatively influence QURE's market standing.
• 10% chance: Disruptive pipeline developments provide unexpected support for stock.

Trading Oracle: Given the expected volatility due to upcoming data reads, consider executing a debit spread on call options: buy QURE $6 calls and sell $7 calls with expiration approximately 30 days out. This balances risk and reward while capitalizing on potential positive AMT-130 news. Alternatively, if bearish sentiment persists, a put spread could hedge risk.

November 29, 2024